

CofC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

US Patent No.: 6,740,522 *B2*
Issued: May 25, 2004
On an Application of: Dirk M. Anderson
Serial No.: 09/865,363
Filed: May 25, 2001
Entitled: ANTIBODIES AGAINST LIGAND FOR RECEPTOR
ACTIVATOR OF NF-KB
Docket No.: 2852-E

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. §1.322 OR 1.323

ATTN: Decision and Certificate of Correction
Branch of the Patent Issue Division
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate
DEC 28 2004
of Correction

Sir:

The patentee of the above-identified patent respectfully requests that you issue a Certificate of Correction to correct certain errors in the patent. Attached are two copies of modified Form PTO-1050 on which the errors are specified with at least one copy being suitable for printing.

The errors occurred during the printing of the patent. Correction thereof does not involve such changes in the patent as would constitute new matter or would require re-examination.

The exact page and line number where the error occurs in the application file are:

<u>SPECIFICATION</u> Page, Line	<u>PATENT</u> Column, Line	<u>ERROR BY:</u> PTO/Patentee
Page 7, line 33	Column 6, line 34	PTO
Page 8, line 1	Column 6, line 40	PTO
Page 12, line 3 (as amended in Amendment After Final Rejection)	Column 10, line 1	PTO
Page 20, line 29	Column 16, line 58	PTO
Page 30, line 3	Column 24, line 34	PTO
Page 32, line 1	Column 25, line 66	PTO
Page 34, line 9	Column 27, line 56	PTO

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

December 16, 2004
Date

DeDeLund
Signature

29 DEC 2004

As the errors noted are on the part of the Office, no fees are believed due in regard to this Request; however, please charge Deposit Account No. 09-0089 for any deficiency in fees. Please charge an additional \$5.00 to Deposit Account No. 09-0089 for 10 additional copies of the issued Certificate of Correction. An original and two copies of this Request are enclosed.

Respectfully submitted,



Diana K. Sheiness
Attorney/Agent for Applicants
Registration No.: 35,356
Phone: (206) 265-7818
Date: December 16, 2004

Please send all future correspondence to:
22932

Immunex Corporation
Law Department
1201 Amgen Court West
Seattle, WA 98119-3105



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

US Patent No.: 6,740,522
Issued: May 25, 2004
On an Application of: Dirk M. Anderson
Serial No.: 09/865,363
Filed: May 25, 2001
Entitled: ANTIBODIES AGAINST LIGAND FOR RECEPTOR
ACTIVATOR OF NF-KB
Docket No.: 2852-E

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. §1.322 OR 1.323

ATTN: Decision and Certificate of Correction
Branch of the Patent Issue Division
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The patentee of the above-identified patent respectfully requests that you issue a Certificate of Correction to correct certain errors in the patent. Attached are two copies of modified Form PTO-1050 on which the errors are specified with at least one copy being suitable for printing.

The errors occurred during the printing of the patent. Correction thereof does not involve such changes in the patent as would constitute new matter or would require re-examination.

The exact page and line number where the error occurs in the application file are:

<u>SPECIFICATION</u> Page, Line	<u>PATENT</u> Column, Line	<u>ERROR BY:</u> PTO/Patentee
Page 7, line 33	Column 6, line 34	PTO
Page 8, line 1	Column 6, line 40	PTO
Page 12, line 3 (as amended in Amendment After Final Rejection)	Column 10, line 1	PTO
Page 20, line 29	Column 16, line 58	PTO
Page 30, line 3	Column 24, line 34	PTO
Page 32, line 1	Column 25, line 66	PTO
Page 34, line 9	Column 27, line 56	PTO

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

December 16, 2004

Date

DeDeLuna

Signature

As the errors noted are on the part of the Office, no fees are believed due in regard to this Request; however, please charge Deposit Account No. 09-0089 for any deficiency in fees. Please charge an additional \$5.00 to Deposit Account No. 09-0089 for 10 additional copies of the issued Certificate of Correction. An original and two copies of this Request are enclosed.


Respectfully submitted,



Diana K. Sheiness
Attorney/Agent for Applicants
Registration No.: 35,356
Phone: (206) 265-7818
Date: December 16, 2004

Please send all future correspondence to:
22932

Immunex Corporation
Law Department
1201 Amgen Court West
Seattle, WA 98119-3105



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

US Patent No.: 6,740,522
Issued: May 25, 2004
On an Application of: Dirk M. Anderson,
Serial No.: 09/865,363
Filed: May 25, 2001
Entitled: ANTIBODIES AGAINST LIGAND FOR RECEPTOR
ACTIVATOR OF NF-KB
Docket No.: 2852-E

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. §1.322 OR 1.323

ATTN: Decision and Certificate of Correction
Branch of the Patent Issue Division
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The patentee of the above-identified patent respectfully requests that you issue a Certificate of Correction to correct certain errors in the patent. Attached are two copies of modified Form PTO-1050 on which the errors are specified with at least one copy being suitable for printing.

The errors occurred during the printing of the patent. Correction thereof does not involve such changes in the patent as would constitute new matter or would require re-examination.

The exact page and line number where the error occurs in the application file are:

<u>SPECIFICATION</u> Page, Line	<u>PATENT</u> Column, Line	<u>ERROR BY:</u> PTO/Patentee
Page 7, line 33	Column 6, line 34	PTO
Page 8, line 1	Column 6, line 40	PTO
Page 12, line 3 (as amended in Amendment After Final Rejection)	Column 10, line 1	PTO
Page 20, line 29	Column 16, line 58	PTO
Page 30, line 3	Column 24, line 34	PTO
Page 32, line 1	Column 25, line 66	PTO
Page 34, line 9	Column 27, line 56	PTO

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

December 16, 2004
Date

[Signature]
Signature

As the errors noted are on the part of the Office, no fees are believed due in regard to this Request; however, please charge Deposit Account No. 09-0089 for any deficiency in fees. Please charge an additional \$5.00 to Deposit Account No. 09-0089 for 10 additional copies of the issued Certificate of Correction. An original and two copies of this Request are enclosed.

Respectfully submitted,



Diana K. Sheiness
Attorney/Agent for Applicants
Registration No.: 35,356
Phone: (206) 265-7818
Date: December 16, 2004

Please send all future correspondence to:
22932

Immunex Corporation
Law Department
1201 Amgen Court West
Seattle, WA 98119-3105

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,740,522 *B2*

DATED : May 25, 2004

INVENTORS : Dirk M. ANDERSON

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 6, line 34, "a-helical" should read -- α -helical --.

Column 6, line 40, "Several studies have indicated...." should start as new paragraph.

Column 10, line 1, delete "to be used, for example, in interfering with RANKL signaling, as components of diagnostic or research assays for RANKL or RANKL activity, or in affinity purification of RANKL."

Column 16, line 58, "(pBluescriptSK³¹)" should read -- (pBluescriptSK⁻) --.

Column 24, line 34, "(1 μ g/ml)" should read -- (1 ng/ml) --, and
"(10 g/ml)" should read -- (10 ng/ml) --.

Column 25, line 66, "Dendritic cells are referred..." should start as new paragraph.

Column 27, line 56, "C57BU6" should read -- C57BL/6 --.

MAILING ADDRESS OF SENDER:

Immunex Corporation
Law Department
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
(805) 447-1000

PATENT NO. 6,740,522 *B2*

No. of add'l copies @ 50¢ per page

⇒ 10

FORM PTO 1050 (MODIFIED)

29 DEC 2004

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,740,522 *B2*
DATED : May 25, 2004
INVENTORS : Dirk M. ANDERSON

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 6, line 34, "a-helical" should read -- α -helical --.

Column 6, line 40, "Several studies have indicated...." should start as new paragraph.

Column 10, line 1, delete "to be used, for example, in interfering with RANKL signaling, as components of diagnostic or research assays for RANKL or RANKL activity, or in affinity purification of RANKL."

Column 16, line 58, "(pBluescriptSK³¹)" should read -- (pBluescriptSK⁻) --.

Column 24, line 34, "(1 μ g/ml)" should read -- (1 ng/ml) --, and
"(10 g/ml)" should read -- (10 ng/ml) --.

Column 25, line 66, "Dendritic cells are referred..." should start as new paragraph.

Column 27, line 56, "C57BU6" should read -- C57BL/6 --.

MAILING ADDRESS OF SENDER:

Immunex Corporation
Law Department
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
(805) 447-1000

PATENT NO. 6,740,522 *B2*

No. of add'l copies @ 50¢ per page

⇒ 10